## ACGL: Arch Capital Group Ltd. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -3.1% below STRENGTH zone (4.0-10.0%); PEG 2.24 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($88.69)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Dymon Asia Capital Singapore PTE. LTD. Takes Position in Arch Capital Group Ltd. $ACGL**
- Source: MarketBeat | 20251210T101330 | Somewhat-Bullish | Relevance: 99%
-  Dymon Asia Capital Singapore PTE. LTD. has acquired a new position of 18,000 shares in Arch Capital Group Ltd. (NASDAQ:ACGL), valued at approximately $1.64 million, making it the fund's 26th largest holding. This comes as Arch Capital Group reported strong quarterly earnings, surpassing analyst expectations with $2.77 EPS. The company holds a "Hold" consensus rating from analysts with an average target price of $106.85.

**2. Wall Street Has a Mixed Opinion on Arch Capital (ACGL), Here's Why**
- Source: Finviz | 20251209T170750 | Neutral | Relevance: 99%
- Wall Street analysts have a mixed opinion on Arch Capital (ACGL) despite recent price target adjustments. Harry Fong of Roth MKM lowered his price target to $110 while reiterating a Buy rating, citing mixed Q3 2025 earnings where revenue missed expectations but EPS topped forecasts. Conversely, Rowland Mayor of RBC Capital initiated coverage with a Buy rating and a $108 price target, acknowledging a potential top-line slowdown but anticipating strong underwriting margins and growing net investment income to offset it.

**3. Arch Capital Group Ltd. $ACGL Shares Acquired by Amundi**
- Source: MarketBeat | 20251208T090827 | Somewhat-Bullish | Relevance: 99%
-  Amundi increased its stake in Arch Capital Group Ltd. (NASDAQ:ACGL) by 1.4% in the second quarter, now owning 1,707,324 shares valued at $150.9 million. The company reported strong quarterly earnings, significantly beating analyst expectations, and has a consensus "Hold" rating with an average target price of $106.85 from analysts. CFO Francois Morin also recently sold 8,000 shares of ACGL stock.

**4. Does Arch Capital Still Offer Value After Specialty Insurance Expansion and Strong Long Term Gains?**
- Source: Simply Wall Street | 20251210T144549 | Bullish | Relevance: 98%
- Arch Capital Group (ACGL) is being assessed for its current valuation after significant long-term gains, with recent expansion into specialty insurance and reinsurance. Despite modest short-term returns, the company shows strong long-term performance and is considered undervalued by two different valuation approaches: Excess Returns Analysis and Price vs. Earnings, suggesting potential for continued value. The article encourages investors to use "Narratives" for personalized valuation based on their own assumptions.

**5. Arch Capital Group Ltd. $ACGL Shares Acquired by Ossiam**
- Source: MarketBeat | 20251210T140723 | Somewhat-Bullish | Relevance: 98%
-  Ossiam increased its stake in Arch Capital Group Ltd. by 124.2% in the second quarter, acquiring an additional 18,006 shares to own a total of 32,509 shares valued at $2.96 million. Other institutional investors like Vanguard Group Inc., Artisan Partners, Geode Capital Management LLC, JPMorgan Chase & Co., and Northern Trust Corp also boosted their holdings in the insurance provider. The article also notes recent insider selling by CFO Francois Morin and provides financial metrics, earnings data, and analyst ratings for Arch Capital Group.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Roth Capital | $110 | $125 | -12% |
| 2025-11-17 | Morgan Stanley | $110 | $105 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Roth Capital | main | Buy |
| 2025-11-17 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($1.62M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 11.7% (-0.2%)
- Blackrock Inc.: 8.9% (-1.4%)
- Artisan Partners Lim: 6.5% (-0.8%)
- BAMCO Inc.: 5.2% (-4.9%)
- State Street Corpora: 4.6% (-1.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.24 elevated, pricing in significant growth expectations. Forward P/E 9.9x stretched relative to 1% growth. Quality metrics strong (margin 21%). Balance sheet: strong liquidity (7513000000.0x), $2.2B free cash flow. Insider selling cluster ($1.6M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $34.3B |
| Beta | 0.45 |
| 52W Range | $82.45 - $97.40 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.24 |
| Forward P/E | 9.9 |
| Current P/E | 10.0 |
| YoY Growth | 0.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.6% to -3.1% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.07% (CS: 32) | Weak |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.009x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.77
- **Stop Loss:** $88.69 (3.4% risk)
- **Target:** $94.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 324
- **Position Value:** $29,733.48
- **Portfolio %:** 29.73%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-10 (Est: $2.33)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.25 | $2.77 | +22.9% |
| 2025Q2 | $2.30 | $2.58 | +12.2% |
| 2025Q1 | $1.31 | $1.54 | +17.2% |
| 2024Q4 | $1.80 | $2.26 | +25.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*